The Express Scripts Holding Company (ESRX) reported fourth quarter non-GAAP EPS of $1.39 after the close Monday, compared to the consensus estimate of $1.38. Revenues increased 2.1% from last year to $26.31 billion. Analysts expected revenues of $25.66 billion. The stock is now down $0.49 to $86.23 on 4.78 million shares.
For Q1’15, ESRX provided EPS guidance of $1.07-$1.11 versus consensus of $1.16 per share. For the full year, the company anticipates achieving adjusted EPS in the range of $5.35 to $5.49, representing growth of 10% to 13% over 2014.
On valuation measures, Express Scripts Holding Co. shares, which currently have an average 3-month trading volume of 3.8 million shares, trade at a trailing-12 P/E of 34.87, a forward P/E of 15.94 and a P/E to growth ratio of 1.34. The median Wall Street price target on the name is $90.00 with a high target of $102.00. Currently ticker boasts 17 ‘Buy’ endorsements, compared to 7 ’Holds’ and no ‘Sell’.
Profitability-wise, ESRX has a t-12 profit and operating margin of 1.92% and 4.41%, respectively. The $63.64 billion market cap company reported $834.80 million in cash vs. $14.69 billion in debt in its most recent quarter.
ESRX currently prints a one year return of about 11.70%, and a year-to-date return of around 1.70%.
The chart below shows where the equity has traded over the last 52 weeks.
Express Scripts Holding Co. provides a range of pharmacy benefit management services primarily in the United States and Canada. The company was founded in 1986 and is headquartered in St. Louis, Missouri.